Can we improve translation of preclinical data to clinical outcomes?

Early in the drug development lifecycle, the process of evaluating compounds for hemodynamic and electrophysiological cardiovascular risk does not follow a regulated guideline, but more of an investigational method. Determining in-vitro assessments that translate to the whole animal and, more importantly, to the clinical outcome is paramount. One approach would be to assess the test article on cardiac electrophysiology and mechanics in assays with increased complexity. With overlapping functional outputs, it may then be possible to assess biomarkers from multiple assays that translate across the complexity of scales from: 1) individual cardiac targets (ion channels, transporters, contractile proteins, and organelles), 2) single cell systems (stem-cell derived human cardiomyocytes (SC-hCMs), cellular integration), 3) isolated hearts (organ integration) to 4) the whole animal (whole body integration).

Please join us for this complementary luncheon seminar where our scientists will discuss an integrated approach to de-risking compounds for cardiovascular liabilities.

Date: October 26, 2017

Time: 11:00 AM – 2:00 PM

Location: San Mateo Marriott San Francisco Airport

1770 S. Amphlett Boulevard

San Mateo, CA 94402

Engage Ballroom